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ABSTRACT
Objectives: The aim of this study was to establish whether early pulmonary rehabilitation after severe
exacerbation of chronic obstructive pulmonary disease (COPD) reduces mortality and hospital admissions,
and increases physical performance and quality of life compared to rehabilitation initiated later in the
stable phase of COPD.
Methods: In a randomised controlled trial of 150 patients hospitalised with an exacerbation of COPD,
participants were allocated to pulmonary rehabilitation either within 2 weeks after discharge or the same
rehabilitation programme but initiated 2 months after discharge.
Results: Early pulmonary rehabilitation did not prolong time to first hospital admission or time to death
(hazard ratio 0.79, 95% CI 0.47–1.23, p=0.33) compared to rehabilitation in stable phase. However,
2 months after inclusion, pulmonary rehabilitation resulted in a significantly better improvement in the
incremental shuttle walk test (33.9 m, 95% CI 4.18–63.7, p=0.02) compared to that in the stable phase.
The difference in the endurance shuttle walk test was of borderline significance (140 s, 95% CI
−2.03–282.76, p=0.05), but there was no significant difference concerning the COPD assessment test
(−1.43 points, 95% CI −3.44–0.59, p=0.17).
Conclusion: Early pulmonary rehabilitation after acute exacerbation of COPD led to a faster improvement
in physical performance compared to rehabilitation initiated later in the stable phase, but did not improve
survival or prolong time to hospital readmission.
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Introduction
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is frequent in severe chronic
obstructive pulmonary disease (COPD). AECOPD is among the most common causes of hospitalisation, it
increases the decline in lung function and repeated exacerbations are associated with higher readmission
rates to hospital and increased mortality [1–3]. Furthermore, severe AECOPD is associated with worsening
of symptoms and impairment of physical and psychological wellbeing [4, 5]. Although symptoms after
AECOPD usually last 7–10 days, about 20% of the patients have not fully recovered after 8 weeks [6].
Pulmonary rehabilitation plays a key role in the management of COPD. It has a significant impact on
reducing symptoms and increasing exercise capacity and quality of life in patients with stable COPD [7].
Due to the deterioration in the patient’s physical performance and quality of life during exacerbation,
pulmonary rehabilitation initiated immediately after AECOPD is expected to show a larger beneficial effect
compared to when it is introduced later in stable COPD. In fact, early pulmonary rehabilitation after
AECOPD seems to reduce the risk of recurrent hospital admissions and mortality, although the results
have not been uniform, and one large study reported increased mortality [8, 9]. However, in spite of great
heterogeneity between the studies, a systematic review by PUHAN et al. [10] in 2016 evaluating the effect of
early rehabilitation compared to no rehabilitation, concluded that pulmonary rehabilitation is an effective
intervention after an exacerbation regarding exercise capacity and health-related quality of life and also
found beneficial effects on mortality and hospital admissions. The investigators suggested that the
heterogeneity between the results could be explained by the difference in the extensiveness of the
rehabilitation programmes and the methodological quality of the studies.
We therefore conducted a randomised controlled trial investigating the effect of a comprehensive and
standardised pulmonary rehabilitation programme initiated within 2 weeks after discharge from hospital
compared to a similar rehabilitation programme initiated in the stable phase, 2–3 months after discharge,
in patients admitted with an AECOPD.
Methods
Study design
This study was an investigator-initiated single centre open-label randomised controlled clinical trial
conducted at the Department of Respiratory Medicine at Gentofte Hospital in Denmark. Approval was
obtained from the local ethics committee (H-2-2013-143) and the study was registered in
ClinicalTrials.gov (NCT02987439). We used sealedenvelope.com to prepare the sequence allocation and
the patients were allocated 1:1 to either early or later pulmonary rehabilitation, using sealed opaque
envelopes. Participants readmitted to hospital during the study were not randomised again but remained
in their initial treatment group.
We assessed data at discharge from hospital at baseline and outcomes at 2 and 6 months follow-up.
Mortality and hospital readmissions were recorded at 12 months.
Primary outcome
Composite outcome of 1-year mortality was measured as all-cause mortality at 12 months and readmission
was defined as at least one hospital readmission due to any cause in the 12-month follow-up period. This
outcome was chosen as it was used in a Cochrane review in 2011 [11].
Secondary outcome
These included: 1-year all-cause mortality and time to death, all-cause hospital readmission and time to
readmission, proportion of participants with at least one hospital readmission due to any cause, hospital
readmission due to a respiratory cause, exercise performance measured by the incremental shuttle walk
test (ISWT) [12] and the endurance shuttle walk test (ESWT) [13], and health-related quality of life
measured by the COPD assessment test (CAT) [14].
General care
During hospitalisation, the participants in both groups were given standard medical treatment for AECOPD,
optimised prescribed medical treatment of COPD and were instructed in chest physiotherapy [15]. At 3 to
7 days after discharge, baseline spirometry (pulmonary function test (PFT)), Medical Research Council
(MRC) dyspnoea scale, CAT, smoking status, ISWT and ESWT were recorded. Information on smoking
cessation was given if relevant. Participants were introduced to a telephone hotline operated by a COPD
nurse during office hours, where they could seek advice about their COPD. At 2 and 6 months after
discharge, smoking status, MRC, CAT, PFT, ISWT and ESWT were recorded.
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Early pulmonary rehabilitation group
After discharge, the participants were referred, according to their physical status, to either outpatient
rehabilitation in the hospital or in the community or rehabilitation at home. Rehabilitation was initiated
within 2 weeks after discharge.
The programme was a standardised 7-week programme with supervised training sessions, consisting of
aerobic exercise and strength training twice weekly for 1.5 h and educational session once per week for
1 h. The programme fulfilled the criteria for pulmonary rehabilitation, according to the Danish Health
Authority and the British Thoracic Society guidelines [16, 17]. The detailed description of the
rehabilitation programme is provided in the supplementary material.
Stable pulmonary rehabilitation group
At the 2-month follow-up, participants in the stable pulmonary rehabilitation group were referred to a
similar programme as undertaken by the early pulmonary rehabilitation group.
Study population
Eligible patients were included consecutively between 2013 and 2016 at the Department of Respiratory
Medicine, Gentofte Hospital. Inclusion criteria were hospitalisation with an AECOPD, a diagnosis of
COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [18], age
>18 years, ability to walk 10 m independently (with or without a walking aid). Exclusion criteria were: life
expectancy <6 months due to another disease (such as cancer or severe heart disease), difficulties in
understanding and speaking Danish (e.g. due to dementia), residence outside Gentofte Hospital’s
recruitment area, discharge to a residence other than their own (e.g. nursing home), participation in
another rehabilitation programme or inability to provide informed consent.
Figure 1 shows a flowchart with the description of the study design.
Statistical analysis
For the sample size calculation, we estimated 1-year mortality in patients without previous hospital
admissions to be 15%, the expected reduction in mortality or readmission rate was set at 25% (power 80%
and α=0.05) leading to a requirement of 112 participants (56 in each group). The effect size was estimated
from the results of the Cochrane review in 2011 [11]. With an estimated dropout frequency of 20%, we
recruited 150 participants. We used STATA 13 (STATA Corporation, College Station, Texas, USA) for the
statistical analyses and analyses of the primary and secondary outcomes were performed according to the
intention-to-treat principle.
Baseline characteristics were analysed with a Student’s t-test or Mann–Whitney U-test for continuous data
and Chi-squared or Fisher’s exact test for categorical data. The primary outcome was analysed with Fine
and Gray competing risk analysis with readmission as failure and death as competing risk. For secondary
outcomes, we used logistic regression for mortality ratio and readmission ratio, log-rank test and Cox
proportional hazards model for survival analysis, and negative binomial regression for relative risk of
readmission between groups. Odds ratios (ORs), hazard ratios (HRs) and incidence rate ratios (IRRs) are
shown with the control group as reference. Longitudinal data were analysed with a mixed-effects model for
CAT, ISWT and ESWT, assuming values were missing at random.
Results
Baseline
We screened 697 patients hospitalised with AECOPD over a 4-year period. We included 150 participants,
with 76 in the early pulmonary rehabilitation group and 74 in the stable pulmonary rehabilitation group.
The main reasons for non-inclusion were: declining to participate, estimated short life expectancy and
participation in other rehabilitation programmes. Figure 2 shows a flow diagram of the progress
throughout the study. One participant was randomised twice by mistake. During the 6-month follow-up
period, 6 and 13 participants were excluded in the early and stable pulmonary rehabilitation groups
respectively, mainly due to a diagnosis of asthma or start of another rehabilitation programme. This
resulted in 70 and 61 participants in the early and stable pulmonary rehabilitation groups, respectively and
all were included in the analysis of the primary end-point.
Baseline characteristics of the participants are presented in table 1 and showed a generally well-balanced
randomisation and they resembles the general COPD population hospitalised with AECOPD in Denmark
[19]. However, participants in the stable pulmonary rehabilitation group had a better CAT score.
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Adherence
In the early pulmonary rehabilitation group, 58 (83%) participants attended at least one rehabilitation
session and 39 (56%) met our a priori definition of adherence (attendance >75% of sessions). The median
time to the first session from discharge was 9 days (interquartile range (IQR) 5–15) with a median number
of sessions of 13 (IQR 8–16). Forty-seven participants received rehabilitation at the hospital’s facilities and
five in the community. Six participants were initially trained in their own homes, but only for a few
sessions and hereafter to complete the programme in the outpatient setup. In the stable pulmonary
rehabilitation group, 32 (53%) had at least one rehabilitation session within 1 year after inclusion with a
median number of sessions of 13 (IQR 10–16) and 21 (34%) participants were adherent. The participants
in the early pulmonary rehabilitation group were significantly more adherent (OR 2.39, 95% CI 1.11–5.18,
p=0.01).
Primary outcome
The primary outcome was a composite end-point of hospitalisation or death. In total, 78 participants (42
in the early and 36 in the stable pulmonary rehabilitation group) met this end-point. Except for one
patient who died without previous hospital admission, all were readmitted at least once in the 12-month
follow-up period. In the competing risk analysis, we found a crude nonsignificant risk (HR 1.03, 95% CI
0.66–1.60, p=0.91) and when adjusted for age, sex, forced expiratory volume in 1 s (FEV1), CAT and
ESWT, there was a nonsignificant risk reduction (HR 0.79, 95% CI 0.47–1.23, p=0.33) (figure 3).
Mortality
Out of the 131 participants, 15 died during the study period, resulting in a 1-year-mortality rate of 11%.
One person was hospitalised and died before the baseline visit, five died of COPD, four of cancer, three of
FIGURE 1 Flowchart of the study
design. COPD: chronic obstructive
pulmonary disease; PR: pulmonary
rehabilitation; AECOPD: acute
exacerbation of COPD; GOLD: Global
Initiative for Chronic Obstructive Lung
Disease; PFT: pulmonary function
test; MRC: medical research council
dyspnoea scale; ISWT: incremental
shuttle walk test; ESWT: endurance
shuttle walk test; CAT: COPD
assessment test.
Treatment of exacerbation during hospitalisation
  Medical treatment of AECOPD according to GOLD document
  Maintenance medical treatment according to GOLD document
  Chest physiotherapy
7 days after discharge
  Home visit by "COPD nurse"
  Lung function test (PFT),
    dyspnoea score (MRC), walk
    test (ISWT and ESWT),
    quality of life (CAT)
7 weeks of outpatient PR
or 
7 weeks of home PR
Intervention group: early PR Control group: stable PR
After 2 months
  Visit in the outpatient clinic
   for lung function test,
    dyspnoea score (MRC), walk
    test (ISWT and ESWT),
    quality of life (CAT)
After 2 months
  Visit in the outpatient clinic
   for lung function test,
    dyspnoea score (MRC), walk
    test (ISWT and ESWT),
    quality of life (CAT)
7 weeks of outpatient PR
After 6 months
  Visit in the outpatient clinic for lung function test, dyspnoea score  
    (MRC), walk test (ISWT and ESWT), quality of life (CAT)
150 patients with COPD hospitalised with an exacerbation were 
included and randomised to either early PR or PR in stable COPD
7 days after discharge
  Home visit by "COPD nurse"
  Lung function test (PFT),
    dyspnoea score (MRC), walk
    test (ISWT and ESWT),
    quality of life (CAT)
After 12 months
  Mortality and hospital admissions were registered
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cardiac causes, one of urosepsis and one of unknown cause. Nine participants died in the early pulmonary
rehabilitation group (13%), and six (10%) in the stable pulmonary rehabilitation group. There were no
significant differences between the groups with an adjusted OR of 1.05 (95% CI 0.33–3.40) p=0.92. A
Kaplan–Meier plot of time to death is shown in figure 4 (log-rank test p=0.59) and using the Cox
proportional hazard model, the adjusted HR was 1.04 (95% CI 0.36–3.01) p=0.95.
TABLE 1 Baseline characteristics
Characteristics Early PR group (n=70) Stable PR group (n=61)
Age years 72.7±9.4 74.4±7.8
Male n (%) 29 (41) 25 (41)
FEV1 L 1.0±0.4 1.0±0.4
FEV1 % predicted 40.2±15 44.1±17
MRC dyspnoea score 3.4±0.9 3.1±0.8
CAT score 16.8±6.0 14.7±5.3
LTOT n (%) 3 (5) 5 (8)
BMI kg·m−2 23.5±4.6 24.2±4.1
Smoking n (%)
Current 22 (31) 15 (25)
Former 45 (64) 43 (70)
Never 3 (4) 3 (5)
Exposure pack-years 40.6±16.5 43.5±19.5
GOLD assessment
Group C n (%) 4 (6) 5 (8)
Group D n (%) 66 (94) 56 (92)
ISWT distance m 186±117 188±110
ESWT time s 216±199 263±210
ESWT level 6.0±3.6 6.3±3.6
Data are presented as mean±SD unless otherwise stated. PR: pulmonary rehabilitation; FEV1: forced
expiratory volume in 1 s; MRC: Medical Research Council; CAT: COPD Assessment Test; LTOT: long-term
oxygen therapy; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease;
ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test.
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Excluded: (n=13)
  Asthma/normal PFT (n=6)
  Another rehabilitation
    programme (n=7)
Excluded: (n=6)
  Asthma/normal PFT (n=4)
  Another rehabilitation
    programme (n=1)
  Randomised twice (n=1)
Allocated to early PR group (n=76) Allocated to stable PR group (n=74)
12 months follow-up (n=61)
for final analysis
12 months follow-up (n=70)
for final analysis
Excluded (n=547)#
150 participants were randomised
697 patients with AECOPD were assessed for eligibility
FIGURE 2 Screening, randomisation and study completion. AECOPD: acute exacerbation of chronic obstructive
pulmonary disease; PR: pulmonary rehabilitation; PFT: pulmonary function test. #: excluded (n=547): declined
to participate (n=125); death in hospital (n=30); life expectancy <6 months (n=134); other rehabilitation
programme (n=126); living in nursing home (n=29); not COPD (n=30); residence outside Gentofte Hospital’s
admission area (n=73).
https://doi.org/10.1183/23120541.00173-2019 5
COPD | J.L. KJÆRGAARD ET AL.
Hospital admissions
During the 1-year follow-up period, 77 (59%) participants had a total of 218 readmissions due to any
cause. In the early pulmonary rehabilitation group, 41 (59%) participants had 128 readmissions versus 36
(60%) in the stable pulmonary rehabilitation group having 90 readmissions. No significant reductions were
found in participants with at least one readmission in the early pulmonary rehabilitation group, showing
an adjusted OR of 0.57 (95% CI 0.25–1.31) p=0.19 and we observed no significant difference in the time
to first hospitalisation, with an adjusted HR of 0.76 (95% CI 0.47–1.24) p=0.28. The number of admissions
was also similar (IRR 1.04 (95% CI 0.66–1.65) p=0.85) in the two groups.
Sixty-two (47%) participants had 151 admissions (86 in the early, versus 65 in the stable, pulmonary
rehabilitation group) due to a respiratory cause (e.g. AECOPD or pneumonia). We found no significant
difference between the groups in participants with at least one respiratory readmission (adjusted OR of
0.66 (95% CI 0.27–1.37) p=0.31) and no difference in the time to respiratory readmission (adjusted HR of
0.78 (95% CI 0.43–1.24) p=0.35).
All analyses on mortality and readmission were adjusted for age, sex and baseline FEV1, CAT and ESWT
and no interactions were found.
Exercise performance and quality of life
For physical performance and quality of life, there was significant improvement in both groups from
baseline at 2 and 6 months (table 2). Although no statistical difference between groups was found at
6 months, the early pulmonary rehabilitation group gained 72 m in the ISWT at 2 months compared to the
FIGURE 3 Cumulative incidence of
hospital readmissions and mortality.
Competing risk analysis (Fine and
Gray) of hospital readmission with
death as competing risk. Adjusted
for age, sex, forced expiratory
volume in 1 s and COPD
Assessment Test. Hazard ratio 0.79
(95% CI 0.47–1.23), p=0.33. Arrows
show the start of pulmonary
rehabilitation (PR).
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FIGURE 4 Mortality. Kaplan–Meier
plot showing survival. Log-rank test
p=0.59. Arrows show the start of
pulmonary rehabilitation (PR).
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gain of 38 m in the stable pulmonary rehabilitation group. This resulted in a difference of 33.9 m (95% CI
4.2–63.7) p=0.02, which is below the minimal clinical important difference (MCID) of 47.5 m [20]. In
addition, there were not a significantly greater number of participants who gained 47.5 m in the
early pulmonary rehabilitation group (responders) (p=0.07). After 6 months, the difference in ISWT
between the two groups diminished to 17.7 m (95% CI −13.3–48.7) p=0.26. There was a trend towards a
larger improvement in ESWT in the early pulmonary rehabilitation group at 2 months (140.4 s (95% CI
−2.0–282.8) p=0.05) but no difference at 6 months (24.3 s (95% CI −123.4–171.9) p=0.75). The MCID of
186–199 s was not reached [21].
Health-related quality of life measured by CAT was not significantly different at either 2 months (−1.4
point (95% CI −3.4–0.6) p=0.17) or 6 months (−1.4 point (95% CI −3.5–0.6) p=0.18) (figure 5).
Discussion
This study demonstrated that initiating a standardised pulmonary rehabilitation programme shortly after
hospitalisation due to severe AECOPD did not improve 1-year survival or reduce 1-year risk of hospital
admissions compared to rehabilitation initiated during the later stable phase. Despite that, we found early
pulmonary rehabilitation to have consistently greater benefit throughout the first 6 months of follow-up
with regard to physical performance assessed by the shuttle walking tests, and additionally, the
participants in the early pulmonary rehabilitation group had significantly higher adherence than those
initiated their rehabilitation later. However, the differences between the groups regarding performance in
the shuttle walking tests diminished after 6 months showing a nonsustained improvement.
TABLE 2 Physical performance and quality of life
Early PR group
change from baseline
Stable PR group
change from baseline
Difference between
groups (95% CI)
p-value
Incremental shuttle
walk test m
Baseline 193.3±8.8 192.7±9.0
2 months 72.4±9.5*** 38.5±9.5*** 33.9 (4.2–63.7) 0.02
6 months 68.1±10.0*** 50.4±10.0*** 17.7 (−13.3–48.7) 0.26
Endurance shuttle
walk test s
Baseline 239±42.4 253±44.1
2 months 399±45.5*** 259±45.6*** 140 (−2.0–282.8) 0.05
6 months 332±47.8*** 307±47.6*** 25 (−123.4–171.9) 0.75
COPD Assessment
Test score
Baseline 15.8±0.5 15.2±0.6
2 months −3.5±0.6** −2.1±0.6** −1.4 (−3.4–0.6) 0.17
6 months −3.6±0.6** −2.2±0.6** −1.4 (−3.5–0.6) 0.18
Data are presented as change from baseline±SE unless otherwise stated. PR: pulmonary rehabilitation.
**: p<0.01; ***: p<0.001.
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FIGURE 5 Exercise capacity and quality of life. Functional measures in a) incremental shuttle walk test and b) endurance shuttle walk test, and c)
quality of life in COPD Assessment Test at baseline, 2 months and 6 months follow-up. PR: pulmonary rehabilitation. *: p<0.05.
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In our study, the stable pulmonary rehabilitation group received the same rehabilitation as the early
intervention group, only differing in timing. Only one study has previously compared early (within
2 weeks of an exacerbation) with late pulmonary rehabilitation (6 months after exacerbation) [22].
However, this study was underpowered due to recruiting issues, but the conclusion supported our results.
The result on primary outcome came out negative. However, the confidence intervals of the results were
wide, suggesting limited confidence that the results confirm lack of effect. The sample size calculation was
derived from the highly positive Cochrane review from 2011 on pulmonary rehabilitation in AECOPD,
which today seems to have overestimated the effects. Estimated from our results, we would have had to
include four times as many participants to see a significant effect of the intervention.
The updated Cochrane review from 2016, European Respiratory Society (ERS)/American Thoracic
Society (ATS) guidelines on the management of COPD exacerbations and a systematic review by RYRSØ
et al. [23, 24] concluded that early pulmonary rehabilitation implemented 3 weeks after discharge, reduced
hospital admissions. But in contrast to these reviews, which compared early pulmonary rehabilitation to
no rehabilitation, the present study compares early to late onset rehabilitation. Even though the
readmission rate was high in our study, with 59% readmitted due to all causes during the 1-year
observation period and 46% due to respiratory causes, we did not find a significant reduction in the risk of
either readmissions or exacerbations. Previous attempts to explain divergent findings in earlier trials
included lack of comprehensiveness in the rehabilitation programme [9, 25]. As our intervention fulfilled
the criteria for a pulmonary rehabilitation programme according to general guidelines, we do not expect it
as a likely explanation for our negative finding.
Further, we did not find reduced mortality, which aligns with the ERS/ATS guideline and Cochrane review
[23]. The mortality in this study was notably low but this is mainly explained by the exclusion of patients
who died in-hospital during admission for AECOPD and before inclusion in the present study.
With regard to exercise capacity, we found a significant improvement in incremental shuttle
walk (ISWT) and borderline significance in endurance shuttle walk (ESWT) after 2 months in participants
who recieved early pulmonary rehabilitation. However, both differences between groups are below the
MCID [20, 21]. At 2 months, which was before initiation of stable rehabilitation, the stable pulmonary
rehabilitation group did show a spontaneous large increase in exercise capacity in both ISWT and ESWT.
An explanation for this could be natural recovery, which has been seen in previous studies, although not
to the same extent [9, 26, 27]. The stable pulmonary rehabilitation group was not allowed to train
elsewhere before the 2-month follow-up and seven participants in that group were excluded due to their
participation in another rehabilitation programme. Further, the stable pulmonary rehabilitation group did
unfortunately not gain the expected effects of the standard rehabilitation programme. This is probably
explained by the low adherence to the rehabilitation programme. The early intervention group had an
expected improvement in COPD assessment test, as seen in other trials but, as mentioned, we also found a
large spontaneous recovery in the stable pulmonary rehabilitation group [28]. Surprisingly, we did not
observe the expected worsening in quality of life after 6 months in the intervention group, as seen in other
studies [14].
The current study was designed to emulate a regular clinical setting with patients referred to the same
standard pulmonary rehabilitation programme as patients with stable COPD, so it would be feasible to
implement in daily clinical practice. Uptake of early pulmonary rehabilitation was acceptable at 83% and
the adherence was significantly higher in the early compared to the stable intervention group, which is
probably explained by the participants’ commitment to rehabilitation shortly after a hospitalisation. It was
possible to refer patients to early pulmonary rehabilitation, but the challenge was to get them to attend the
rehabilitation sessions, even though transportation to the rehabilitation centre was arranged for free.
A key limitation in the current study was the exclusion of eight participants during the study period,
mainly due to misclassification of COPD (e.g. at follow-up, they presented a normalised spirometry or a
substantial reversibility and thereby fulfilled criteria for asthma)
Another limitation was a similar recruiting problem as seen in other studies investigating the effect of
rehabilitation in exacerbations of COPD [22, 29]. Hospital admissions due to exacerbation of COPD in
Denmark usually last 3–4 days, and as the patients were asked to participate within the first couple of days
after admission; rehabilitation may have seemed overwhelming, which made some patients decline
participation, as also seen in other trials [30, 31]. This is a known problem when evaluating pulmonary
rehabilitation in an acute setting and may results in a selection bias, making the included participants not
representative of the general COPD population. The uptake of early rehabilitation needs to be investigated
further especially in the most symptomatic patients (e.g. a referral visit within 1 week after discharge when
the patients have recovered from the most severe part of the exacerbation).
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Conclusion
We found that early pulmonary rehabilitation after severe exacerbation of COPD seems to accelerate the
recovery of exercise capacity, assessed as ISWT, compared to pulmonary rehabilitation initiated later in the
stable phase. In addition, we found that early pulmonary rehabilitation was safe and associated with higher
adherence to the rehabilitation programme. However, we did not find any effect on mortality or hospital
readmission rate.
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